Allergic Conjunctivitis - Drug Pipeline Landscape, 2023

Allergic Conjunctivitis - Drug Pipeline Landscape, 2023

Allergic conjunctivitis is inflammation of the conjunctiva caused by an allergic reaction. Allergic conjunctivitis is caused by allergens and irritants, such as pollen, dust and mold. Allergic conjunctivitis can be grouped into two types seasonal allergic conjunctivitis and perennial allergic conjunctivitis.

Symptoms of allergic conjunctivitis include red or pink eyes, pain, itchiness, swollen eyelids and soreness.

Diagnostic tests of allergic conjunctivitis include an allergy skin test, a blood test and a scraping of conjunctival tissue may be taken to examine your white blood cells.

Drug treatment includes antihistamines, mast cell stabilizers, and occasionally, corticosteroids. Antihistamines may help bring fast relief from symptoms.

The companies active in development of Allergic Conjunctivitis Drugs are Aldeyra Therapeutics, Inc., Inmunotek, Regeneron Pharmaceuticals, Vanda Pharmaceuticals, and Santen Pharmaceutical Co., Ltd.

There are many clinical trials currently ongoing in Allergic Conjunctivitis Drug Development. Some of the most promising and well-designed trials are studying new medications and treatments for allergic conjunctivitis. These trials are testing the safety and effectiveness of these new medications and treatments, and they hold the potential to improve the quality of life for people with allergic conjunctivitis.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Allergic Conjunctivitis treatment such as REGN1908-1909, Reproxalap, VSJ-110 and others. Key players involved in the development of therapies to treat Allergic Conjunctivitis are Aldeyra Therapeutics, Inc, Allakos, Inmunotek, Regeneron Pharmaceuticals, Vanda Pharmaceuticals and others. Five drugs are under late-stage Phase III clinical trials and one drug is in Phase II clinical trials and some other drugs are under Phase I clinical stages of development.

In October 2022, Aldeyra Therapeutics announced oral presentation of Reproxalap phase 3 data at the American Academy of Optometry 2022 annual meeting.

Report Highlights

Global Insight Service's, Allergic Conjunctivitis - Drug Pipeline Landscape, 2023 report provides an overview of the Allergic conjunctivitis pipeline drugs. This report covers detailed insights on Allergic Conjunctivitis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Allergic Conjunctivitis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.